Aktis Oncology grants 37,866 stock options to director
Aktis Oncology director Glenn Gormley received a grant of 37,866 stock options to buy common stock at an exercise price of $18.09 per share.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Aktis Oncology director Glenn Gormley received a grant of 37,866 stock options to buy common stock at an exercise price of $18.09 per share. The options expire on April 15, 2036. According to the vesting terms, one-third vests on April 15, 2027 and the remaining shares vest in equal annual installments thereafter, subject to his continuous service through each vesting date.
Insider Trade Summary
Grant/Award: 37,866 shares
Grant/Award
1 txn
Insider
Gormley Glenn
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 37,866 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 37,866 contracts (Direct)
Holdings Before and After:
Stock Option (Right to Buy), 0 to 37,866 contracts (Direct)
Footnotes (1)
- F1. 1/3 of the original number of shares subject to the option shall vest on April 15, 2027, and 1/3 of the original number of shares subject to the option shall vest in equal annual installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.
Key Figures
Stock options granted: 37,866 options
Exercise price: $18.09 per share
Post-transaction derivative holdings: 37,866 options
+2 more
5 metrics
Stock options granted
37,866 options
Grant to director Glenn Gormley reported on Form 4
Exercise price
$18.09 per share
Strike price for newly granted stock options
Post-transaction derivative holdings
37,866 options
Total options held directly after grant
Option expiration date
April 15, 2036
Final expiration for this option award
Initial vesting date
April 15, 2027
One-third of options vest on this date
Key Terms
Stock Option (Right to Buy), Common Stock, vesting, exercise price
4 terms
Stock Option (Right to Buy) financial
"Security title is listed as "Stock Option (Right to Buy)" for this grant"
Common Stock financial
"Each option is exercisable into shares of the company’s Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
vesting financial
"One-third of the option shall vest in 2027 and the rest in equal annual installments thereafter"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
exercise price financial
"The options have an exercise price of $18.09 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Aktis Oncology (AKTS) report for Glenn Gormley?
Aktis Oncology reported a grant of 37,866 stock options to director Glenn Gormley. These options allow him to buy common shares at $18.09 per share, providing equity-based compensation that aligns his interests with long-term shareholder value.
What is the exercise price of Glenn Gormley’s Aktis Oncology (AKTS) stock options?
The stock options granted to Glenn Gormley have an exercise price of $18.09 per share. This means he can purchase Aktis Oncology common stock at $18.09 once the options vest and remain outstanding, subject to the specified vesting schedule and expiration date.
How many Aktis Oncology (AKTS) options does Glenn Gormley hold after this Form 4?
After the reported grant, Glenn Gormley holds 37,866 stock options directly. Each option is exercisable for one share of Aktis Oncology common stock, contingent on vesting conditions and remaining valid until the April 15, 2036 expiration date.
What is the vesting schedule for Glenn Gormley’s Aktis Oncology (AKTS) option grant?
One-third of the original 37,866 options will vest on April 15, 2027. The remaining two-thirds will vest in equal annual installments thereafter, provided Glenn Gormley maintains continuous service with Aktis Oncology through each applicable vesting date.
When do Glenn Gormley’s Aktis Oncology (AKTS) stock options expire?
The granted stock options are scheduled to expire on April 15, 2036. After this expiration date, any unexercised options will lapse, so potential value from the award depends on vesting, continued service, and the company’s share price before that time.
AI-generated analysis. How Rhea-AI works. Not financial advice.
